Hospital For Special Surgery
- Type
- Teaching hospital
- Where
- New York, NY
- Medicare CCN
- 330270
- Received
- $4,382,119 in 447 records, 2021 ($2,060,695 general, $2,321,424 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: HOSPITAL FOR SPECIAL SURGERY Fuzzy (name and state)
- Lobbying client: HOSPITAL FOR SPECIAL SURGERY Fuzzy (name and state)
- Lobbying client: HOSPITAL FOR SPECIAL SURGERY Fuzzy (name and state)
- Lobbying client: HOSPITAL FOR SPECIAL SURGERY Fuzzy (name and state)
- Lobbying client: HOSPITAL FOR SPECIAL SURGERY Fuzzy (name and state)
- Patent assignee: Hospital for Special Surgery Fuzzy (name and state)
- Trademark owner: Hospital for Special Surgery Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 224 | $2,060,695 |
| 2021 | Research payment | 223 | $2,321,424 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 223 | $2,321,424 |
| Grant | 69 | $683,017 |
| Royalty or License | 17 | $549,778 |
| Space rental or facility fees (teaching hospital only) | 77 | $481,165 |
| Consulting Fee | 6 | $202,585 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 21 | $71,570 |
| Education | 1 | $25,000 |
| Long term medical supply or device loan | 19 | $23,564 |
| Charitable Contribution | 1 | $13,552 |
| Debt forgiveness | 13 | $10,461 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | AstraZeneca UK Limited | $8,450 | Research payment | In-kind items and services | SAPHNELO Biological, Inflammation and Autoimmunity | The purpose of this study is to characterise longterm safety and tolerability of intravenous anifrolumab A Multicentre R | 2021 |
| 2021-12-31 | SI-BONE, INC. | $6,710 | Research payment | Cash or cash equivalent | IFUSE IMPLANT Device, SACROILIAC JOINT DYSFUNCTION | SILVIA | 2021 |
| 2021-12-31 | SI-BONE, INC. | $4,860 | Research payment | Cash or cash equivalent | IFUSE IMPLANT Device, SACROILIAC JOINT DYSFUNCTION | SILVIA | 2021 |
| 2021-12-31 | SI-BONE, INC. | $4,235 | Research payment | Cash or cash equivalent | IFUSE IMPLANT Device, SACROILIAC JOINT DYSFUNCTION | SILVIA | 2021 |
| 2021-12-31 | SI-BONE, INC. | $3,955 | Research payment | Cash or cash equivalent | IFUSE IMPLANT Device, SACROILIAC JOINT DYSFUNCTION | SILVIA | 2021 |
| 2021-12-31 | SI-BONE, INC. | $2,945 | Research payment | Cash or cash equivalent | IFUSE IMPLANT Device, SACROILIAC JOINT DYSFUNCTION | SILVIA | 2021 |
| 2021-12-31 | SI-BONE, INC. | $2,745 | Research payment | Cash or cash equivalent | IFUSE IMPLANT Device, SACROILIAC JOINT DYSFUNCTION | SILVIA | 2021 |
| 2021-12-31 | SI-BONE, INC. | $1,770 | Research payment | Cash or cash equivalent | IFUSE IMPLANT Device, SACROILIAC JOINT DYSFUNCTION | SILVIA | 2021 |
| 2021-12-31 | SI-BONE, INC. | $810 | Research payment | Cash or cash equivalent | IFUSE IMPLANT Device, SACROILIAC JOINT DYSFUNCTION | SILVIA | 2021 |
| 2021-12-31 | SI-BONE, INC. | $810 | Research payment | Cash or cash equivalent | IFUSE IMPLANT Device, SACROILIAC JOINT DYSFUNCTION | SILVIA | 2021 |
| 2021-12-31 | Stryker Corporation | $546 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-12-31 | Masimo Corporation | $1 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2021 | |
| 2021-12-31 | Masimo Corporation | $1 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2021 | |
| 2021-12-31 | Masimo Corporation | $1 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2021 | |
| 2021-12-31 | Masimo Corporation | $0 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2021 | |
| 2021-12-31 | Masimo Corporation | $0 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2021 | |
| 2021-12-31 | Masimo Corporation | $0 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2021 | |
| 2021-12-31 | Masimo Corporation | $0 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2021 | |
| 2021-12-31 | Masimo Corporation | $0 | Long term medical supply or device loan | In-kind items and services | SedLine Device, Devices | 2021 | |
| 2021-12-31 | Masimo Corporation | $0 | Long term medical supply or device loan | In-kind items and services | SedLine Device, Devices | 2021 | |
| 2021-12-31 | Masimo Corporation | $0 | Long term medical supply or device loan | In-kind items and services | SedLine Device, Devices | 2021 | |
| 2021-12-28 | E.R. Squibb & Sons, L.L.C. | $13,552 | Charitable Contribution | Cash or cash equivalent | 2021 | ||
| 2021-12-28 | E.R. Squibb & Sons, L.L.C. | $13,552 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-12-24 | Amgen Inc. | $25,000 | Education | Cash or cash equivalent | 2021 | ||
| 2021-12-23 | DePuy Synthes Products, Inc. | $11,565 | Royalty or License | Cash or cash equivalent | 2021 | ||
| 2021-12-23 | Medical Device Business Services, Inc. | $2,000 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-12-22 | Zimmer Biomet Holdings, Inc. | $5,850 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Juggerknot-Sports Medicine Device, Sports Medicine | 2021 | |
| 2021-12-22 | Johnson & Johnson Health Care Systems Inc. | $545 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-12-22 | UCB SA | $67 | Research payment | Cash or cash equivalent | Phase 3, Multicenter, Randomized, Double-Blind, PBO-Controlled Study of Efficacy, Safety, and Tolerability of Zilucoplan | 2021 | |
| 2021-12-21 | SANOFI US SERVICES INC. | $2,905 | Research payment | Cash or cash equivalent | REZUROCK Drug, Oncology | A Phase 2 Randomized Placebo controlled Double blind Open label Extension Multicenter Study to Evaluate the Efficacy and | 2021 |
| 2021-12-16 | PFIZER INC. | $25,000 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-12-16 | Stryker Corporation | $21,791 | Research payment | Cash or cash equivalent | T2 Device, TRAUMA & EXTREMETIES | METAL ION LEVELS IN STRYKER TRIDENT II TRITANIUM SYSTEM WITH MDM LINER, CERAMIC HEAD, AND ACCOLADE II OR SECURFIT ADVANC | 2021 |
| 2021-12-16 | Medical Device Business Services, Inc. | $10,000 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-12-16 | Medical Device Business Services, Inc. | $10,000 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-12-16 | Stryker Corporation | $5,685 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-12-16 | Smith+Nephew, Inc. | $4,465 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LENS Device, Sports Med Visualization | 2021 | |
| 2021-12-16 | Medical Device Business Services, Inc. | $1,250 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-12-15 | Takeda Pharmaceuticals U.S.A., Inc. | $2,005 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2021 |
| 2021-12-15 | Takeda Pharmaceuticals U.S.A., Inc. | $1,660 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2021 |
| 2021-12-15 | Takeda Pharmaceuticals U.S.A., Inc. | $1,024 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2021 |
| 2021-12-15 | Ortho Development Corporation | $824 | Royalty or License | Cash or cash equivalent | Pagoda Device, ORTHOPEDIC DEVICE | 2021 | |
| 2021-12-09 | Horizon Therapeutics plc | $14,400 | Research payment | Cash or cash equivalent | UPLIZNA Drug, UPLIZNA | VIB0551.P3.S1 | 2021 |
| 2021-12-09 | UCB SA | $270 | Research payment | Cash or cash equivalent | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE ROZANOLIXIZUMAB IN STUDY PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS | 2021 | |
| 2021-12-08 | Zimmer Biomet Holdings, Inc. | $5,518 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Arcos Device, Hips | 2021 | |
| 2021-12-08 | Zimmer Biomet Holdings, Inc. | $3,000 | Grant | Cash or cash equivalent | Grants Device, General | 2021 | |
| 2021-12-03 | SANOFI US SERVICES INC. | $3,411 | Research payment | Cash or cash equivalent | REZUROCK Drug, Oncology | A Phase 2 Randomized Placebo controlled Double blind Open label Extension Multicenter Study to Evaluate the Efficacy and | 2021 |
| 2021-12-03 | SANOFI US SERVICES INC. | $1,975 | Research payment | Cash or cash equivalent | REZUROCK Drug, Oncology | A Phase 2 Randomized Placebo controlled Double blind Open label Extension Multicenter Study to Evaluate the Efficacy and | 2021 |
| 2021-12-03 | SANOFI US SERVICES INC. | $1,296 | Research payment | Cash or cash equivalent | REZUROCK Drug, Oncology | A Phase 2 Randomized Placebo controlled Double blind Open label Extension Multicenter Study to Evaluate the Efficacy and | 2021 |
| 2021-12-02 | Stryker Corporation | $19,065 | Research payment | Cash or cash equivalent | TRIATHLON Device, KNEES | MAVRIC MAGNETIC RESONANCE IMAGING USED TO STUDY DETAILED BONE APPOSITION AND FIXATION OF THE STRYKER TRIATHLON CEMENTLES | 2021 |
| 2021-12-02 | Stryker Corporation | $19,065 | Research payment | Cash or cash equivalent | TRIATHLON Device, KNEES | MAVRIC MAGNETIC RESONANCE IMAGING USED TO STUDY DETAILED BONE APPOSITION AND FIXATION OF THE STRYKER TRIATHLON CEMENTLES | 2021 |
| 2021-12-02 | Stryker Corporation | $19,065 | Research payment | Cash or cash equivalent | TRIATHLON Device, KNEES | MAVRIC MAGNETIC RESONANCE IMAGING USED TO STUDY DETAILED BONE APPOSITION AND FIXATION OF THE STRYKER TRIATHLON CEMENTLES | 2021 |
| 2021-12-02 | Stryker Corporation | $12,710 | Research payment | Cash or cash equivalent | TRIATHLON Device, KNEES | MAVRIC MAGNETIC RESONANCE IMAGING USED TO STUDY DETAILED BONE APPOSITION AND FIXATION OF THE STRYKER TRIATHLON CEMENTLES | 2021 |
| 2021-12-02 | Stryker Corporation | $145 | Research payment | Cash or cash equivalent | RESTORATION Device, HIPS | RESTORATION; ANATOMIC DUAL MOBILITY (ADM) X3; ACETABULAR SYSTEM STUDY WITH LONG TERM DATA COLLECTION FOR THE ACCOLADE; I | 2021 |
| 2021-12-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | $114 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Extension | 2021 |
| 2021-12-01 | Johnson & Johnson Health Care Systems Inc. | $26 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-11-30 | Apos US Management Inc. | $20,564 | Research payment | Cash or cash equivalent | AposHealth Device, Musculoskeletal | Apos knee pain | 2021 |
| 2021-11-30 | Medical Device Business Services, Inc. | $500 | Research payment | Cash or cash equivalent | Kincise Device, Ortho-Hip | Prospective Randomized Multi Center Post Market study of Anterior Advantage Surgical Approach in Total Hip Arthroplasty | 2021 |
| 2021-11-24 | Smith+Nephew, Inc. | $715 | Research payment | Cash or cash equivalent | FAST-FIX FLEX Device, Sports Med Knee | A Prospective, Multi-Center Clinical Study to Evaluate the Safety and Performance of the Fast-Fix Flex System for Menisc | 2021 |
| 2021-11-24 | Alexion Pharmaceuticals, Inc. | $50 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravuli | 2021 | |
| 2021-11-18 | Siemens Medical Solutions USA, Inc. | $150,000 | Research payment | Cash or cash equivalent | HSS_Potter_MSK_Clinical_MR_2021 | 2021 | |
| 2021-11-18 | Stryker Corporation | $194 | Research payment | Cash or cash equivalent | TRIDENT Device, HIPS | TRIDENT II TRITANIUM OUTCOMES STUDY | 2021 |
| 2021-11-17 | Smith+Nephew, Inc. | $4,719 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | REDAPT Device, Recon Hips | 2021 | |
| 2021-11-17 | Smith+Nephew, Inc. | $4,504 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | JOURNEY UNI Device, Recon Knees | 2021 | |
| 2021-11-17 | Smith+Nephew, Inc. | $3,020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JOURNEY UNI Device, Recon Knees | 2021 | |
| 2021-11-17 | Smith+Nephew, Inc. | $2,480 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REDAPT Device, Recon Hips | 2021 | |
| 2021-11-15 | Ortho Development Corporation | $1,613 | Royalty or License | Cash or cash equivalent | Pagoda Device, ORTHOPEDIC DEVICE | 2021 | |
| 2021-11-15 | Takeda Pharmaceuticals U.S.A., Inc. | $250 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2021 |
| 2021-11-10 | Smith+Nephew, Inc. | $23,166 | Research payment | Cash or cash equivalent | OR3O Device, Recon Hips | Prospective Multi-Center study to evaluate the safety and effectiveness of the OR30 Dual Mobility system in primary and | 2021 |
| 2021-11-10 | Stryker Corporation | $8,671 | Research payment | Cash or cash equivalent | MAKO Device, KNEES, HIPS | ALIGNMENT AND CLINICAL OUTCOMES OF ROBOTIC ARM ASSISTED TOTAL KNEE ARTHROPLASTY | 2021 |
| 2021-11-10 | Smith+Nephew, Inc. | $2,261 | Research payment | Cash or cash equivalent | OR3O Device, Recon Hips | Prospective Multi-Center study to evaluate the safety and effectiveness of the OR30 Dual Mobility system in primary and | 2021 |
| 2021-11-09 | UCB SA | $8,208 | Research payment | Cash or cash equivalent | Phase 3, Multicenter, Randomized, Double-Blind, PBO-Controlled Study of Efficacy, Safety, and Tolerability of Zilucoplan | 2021 | |
| 2021-11-09 | UCB SA | $2,011 | Research payment | Cash or cash equivalent | Phase 3, Multicenter, Randomized, Double-Blind, PBO-Controlled Study of Efficacy, Safety, and Tolerability of Zilucoplan | 2021 | |
| 2021-11-09 | UCB SA | $191 | Research payment | Cash or cash equivalent | Phase 3, Multicenter, Randomized, Double-Blind, PBO-Controlled Study of Efficacy, Safety, and Tolerability of Zilucoplan | 2021 | |
| 2021-11-08 | Smith+Nephew, Inc. | $10,084 | Research payment | Cash or cash equivalent | OR3O Device, Recon Hips | Prospective Multi-Center study to evaluate the safety and effectiveness of the OR30 Dual Mobility system in primary and | 2021 |
| 2021-11-08 | Medical Device Business Services, Inc. | $6,532 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-11-08 | Medical Device Business Services, Inc. | $6,500 | Research payment | Cash or cash equivalent | ACTIS Device, Ortho-Hip | Actis Total Hip System 2 Year Follow up | 2021 |
| 2021-11-08 | Medical Device Business Services, Inc. | $5,310 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-11-08 | Medical Device Business Services, Inc. | $3,000 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-11-08 | Smith+Nephew, Inc. | $1,670 | Research payment | Cash or cash equivalent | REDAPT Device, Recon Hips | A Multicenter, Post Market Clinical Follow-up Study of Subjects with the REDAPT Revision Monolithic Sleeveless Stem and/ | 2021 |
| 2021-11-08 | UCB SA | $263 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF ROZANOLIXIZU | 2021 | |
| 2021-11-05 | Siemens Medical Solutions USA, Inc. | $13,983 | Grant | In-kind items and services | 2021 | ||
| 2021-11-05 | TREACE MEDICAL CONCEPTS, INC. | $5,972 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Lapiplasty System Device, Y | 2021 | |
| 2021-11-04 | Medtronic, Inc. | $26,688 | Research payment | Cash or cash equivalent | Investigator Sponsored Research | 2021 | |
| 2021-11-04 | Medtronic, Inc. | $26,688 | Research payment | Cash or cash equivalent | Investigator Sponsored Research | 2021 | |
| 2021-11-04 | Stryker Corporation | $9,555 | Research payment | Cash or cash equivalent | MAKO Device, KNEES, HIPS | SURVIVORSHIP AND OUTCOMES OF ROBOTIC ARM ASSISTED MEDIAL UKA | 2021 |
| 2021-11-04 | Stryker Corporation | $9,555 | Research payment | Cash or cash equivalent | MAKO Device, KNEES, HIPS | SURVIVORSHIP AND OUTCOMES OF ROBOTIC ARM ASSISTED MEDIAL UKA | 2021 |
| 2021-11-04 | Stryker Corporation | $4,465 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | MAKO Device, KNEES, HIPS | 2021 | |
| 2021-11-04 | Kadmon Corporation LLC | $3,956 | Research payment | In-kind items and services | A Phase 2 Randomized Placebo controlled Double blind Open label Extension Multicenter Study to Evaluate the Efficacy and | 2021 | |
| 2021-11-03 | Smith+Nephew, Inc. | $1,670 | Research payment | Cash or cash equivalent | FAST-FIX FLEX Device, Sports Med Knee | A Prospective, Multi-Center Clinical Study to Evaluate the Safety and Performance of the Fast-Fix Flex System for Menisc | 2021 |
| 2021-11-03 | Alexion Pharmaceuticals, Inc. | $250 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension | 2021 | |
| 2021-11-03 | Johnson & Johnson Health Care Systems Inc. | $46 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-11-03 | Johnson & Johnson Health Care Systems Inc. | $1 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-11-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | $116 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Extension | 2021 |
| 2021-10-29 | Medical Device Business Services, Inc. | $4,381 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-10-28 | Smith+Nephew, Inc. | $1,670 | Research payment | Cash or cash equivalent | BIRMINGHAM HIP Device, Recon Hips | A Post-Approval Study of the Birmingham Hip Resurfacing (BHR) Radiological System Review | 2021 |
| 2021-10-28 | Stryker Corporation | $1,475 | Research payment | Cash or cash equivalent | RESTORATION Device, HIPS | RESTORATION; ANATOMIC DUAL MOBILITY (ADM) X3; ACETABULAR SYSTEM STUDY WITH LONG TERM DATA COLLECTION FOR THE ACCOLADE; I | 2021 |
| 2021-10-27 | Medical Device Business Services, Inc. | $300 | Research payment | Cash or cash equivalent | ACTIS Device, Ortho-Hip | Actis Total Hip System 2 Year Follow up | 2021 |
| 2021-10-26 | UCB SA | $816 | Research payment | In-kind items and services | A DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED, 18 MONTH PHASE 2A STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, | 2021 | |
| 2021-10-21 | UCB SA | $13,947 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF ROZANOLIXIZU | 2021 | |
| 2021-10-21 | UCB SA | $6,693 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBL-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT | 2021 | |
| 2021-10-21 | Smith+Nephew, Inc. | $4,283 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | WEREWOLF Device, Sports Med Resection | 2021 | |
| 2021-10-21 | Smith+Nephew, Inc. | $878 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | WEREWOLF Device, Sports Med Resection | 2021 | |
| 2021-10-20 | AstraZeneca Pharmaceuticals LP | $337 | Research payment | Cash or cash equivalent | FASENRA Biological, Respiratory | A Randomised, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Sa | 2021 |
| 2021-10-20 | Alexion Pharmaceuticals, Inc. | $135 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension | 2021 | |
| 2021-10-18 | Gilead Sciences, Inc. | $416,135 | Research payment | Cash or cash equivalent | SLE: ELISA and STING Flow Cytometry | 2021 | |
| 2021-10-18 | Limacorporate S.p.A. | $50,000 | Consulting Fee | Cash or cash equivalent | PHYSICA CR Device, Devices | 2021 | |
| 2021-10-18 | Gilead Sciences, Inc. | $9,000 | Research payment | Cash or cash equivalent | SLE: ELISA and STING Flow Cytometry | 2021 | |
| 2021-10-15 | Smith+Nephew, Inc. | $11,377 | Research payment | Cash or cash equivalent | OXINIUM Hip Device, Recon Hips | A Multi-Center, Randomized Controlled Study of Efficacy and Safety of the OXINIUM DH Total Hip Replacement System in Sub | 2021 |
| 2021-10-15 | Ortho Development Corporation | $755 | Royalty or License | Cash or cash equivalent | Pagoda Device, ORTHOPEDIC DEVICE | 2021 | |
| 2021-10-13 | Takeda Pharmaceuticals U.S.A., Inc. | $1,762 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2021 |
| 2021-10-13 | Takeda Pharmaceuticals U.S.A., Inc. | $745 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2021 |
| 2021-10-13 | Takeda Pharmaceuticals U.S.A., Inc. | $419 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2021 |
| 2021-10-08 | Stryker Corporation | $19,065 | Research payment | Cash or cash equivalent | TRITANIUM Device, HIPS | MAVRIC MAGNETIC RESONANCE IMAGING USED TO STUDY DETAILED BONE APPOSITION AND FIXATION OF THE STRYKER TRIATHLON CEMENTLES | 2021 |
| 2021-10-08 | Stryker Corporation | $19,065 | Research payment | Cash or cash equivalent | TRITANIUM Device, HIPS | MAVRIC MAGNETIC RESONANCE IMAGING USED TO STUDY DETAILED BONE APPOSITION AND FIXATION OF THE STRYKER TRIATHLON CEMENTLES | 2021 |
| 2021-10-08 | Stryker Corporation | $19,065 | Research payment | Cash or cash equivalent | TRITANIUM Device, HIPS | MAVRIC MAGNETIC RESONANCE IMAGING USED TO STUDY DETAILED BONE APPOSITION AND FIXATION OF THE STRYKER TRIATHLON CEMENTLES | 2021 |
| 2021-10-08 | Stryker Corporation | $12,710 | Research payment | Cash or cash equivalent | TRITANIUM Device, HIPS | MAVRIC MAGNETIC RESONANCE IMAGING USED TO STUDY DETAILED BONE APPOSITION AND FIXATION OF THE STRYKER TRIATHLON CEMENTLES | 2021 |
| 2021-10-06 | Masimo Corporation | $3,297 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2021 | |
| 2021-10-04 | UCB SA | $12,900 | Research payment | Cash or cash equivalent | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE ROZANOLIXIZUMAB IN STUDY PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS | 2021 | |
| 2021-10-04 | Alexion Pharmaceuticals, Inc. | $2,281 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension | 2021 | |
| 2021-10-04 | UCB SA | $1,500 | Research payment | Cash or cash equivalent | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE ROZANOLIXIZUMAB IN STUDY PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS | 2021 | |
| 2021-10-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | $116 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Extension | 2021 |
| 2021-09-30 | EXACTECH, INC. | $154,068 | Royalty or License | Cash or cash equivalent | TRULIANT Device, ORTHOPAEDIC | 2021 | |
| 2021-09-30 | Arthrex, Inc. | $10,000 | Research payment | Cash or cash equivalent | SHOULDER IMPLANTS FIBERTAK KNOTTED Device, SHOULDER - IMPLANTS - FIBERTAK - KNOTTED | Longitudinal Outcome Assessment of All-Suture Anchor Medial Row Fixation for RCR IICS/200 | 2021 |
| 2021-09-30 | Engage Uni, LLC | $4,381 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Engage Partial Knee System Device, Recon Knees | 2021 | |
| 2021-09-30 | MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. | $2,750 | Research payment | Cash or cash equivalent | SAFETY STUDY OF ORAL EDARAVONE ADMINISTERED IN SUBJECTS WITH ALS | 2021 | |
| 2021-09-29 | Bio-Rad Laboratories, Inc. | $799 | Debt forgiveness | Cash or cash equivalent | Seraclone Anti-A (ABO1) Device, Blood Typing | 2021 | |
| 2021-09-27 | DePuy Synthes Products, Inc. | $11,827 | Royalty or License | Cash or cash equivalent | 2021 | ||
| 2021-09-27 | UOC USA INC | $275 | Consulting Fee | Cash or cash equivalent | U-Motion II, UTF Device, UOC Hip System | 2021 | |
| 2021-09-21 | Orthofix Medical, Inc. | $250 | Research payment | Cash or cash equivalent | M6-C Device, Prosthesis, Intervertebral Disc | M6-C Post Approval Study (PAS)- CA-C004 | 2021 |
| 2021-09-20 | Medical Device Business Services, Inc. | $6,861 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-09-16 | UCB SA | $500 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBL-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT | 2021 | |
| 2021-09-15 | Ortho Development Corporation | $678 | Royalty or License | Cash or cash equivalent | Pagoda Device, ORTHOPEDIC DEVICE | 2021 | |
| 2021-09-14 | Smith+Nephew, Inc. | $6,272 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-09-14 | Smith+Nephew, Inc. | $5,011 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-09-14 | Smith+Nephew, Inc. | $4,946 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LENS Device, Sports Med Visualization | 2021 | |
| 2021-09-14 | Smith+Nephew, Inc. | $4,296 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LENS Device, Sports Med Visualization | 2021 | |
| 2021-09-14 | Smith+Nephew, Inc. | $4,212 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LENS Device, Sports Med Visualization | 2021 | |
| 2021-09-14 | EXACTECH, INC. | $2,630 | Research payment | Cash or cash equivalent | TRULIANT Device, ORTHOPAEDIC | 2021 | |
| 2021-09-14 | Smith+Nephew, Inc. | $2,628 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-09-14 | Takeda Pharmaceuticals U.S.A., Inc. | $1,829 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2021 |
| 2021-09-14 | Takeda Pharmaceuticals U.S.A., Inc. | $1,795 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2021 |
| 2021-09-14 | Takeda Pharmaceuticals U.S.A., Inc. | $1,716 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2021 |
| 2021-09-14 | Smith+Nephew, Inc. | $1,060 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LENS Device, Sports Med Visualization | 2021 | |
| 2021-09-14 | Smith+Nephew, Inc. | $878 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LENS Device, Sports Med Visualization | 2021 | |
| 2021-09-14 | Takeda Pharmaceuticals U.S.A., Inc. | $618 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2021 |
| 2021-09-14 | Smith+Nephew, Inc. | $525 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LENS Device, Sports Med Visualization | 2021 | |
| 2021-09-14 | Smith+Nephew, Inc. | $525 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-09-14 | Takeda Pharmaceuticals U.S.A., Inc. | $88 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2021 |
| 2021-09-14 | Takeda Pharmaceuticals U.S.A., Inc. | $50 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2021 |
| 2021-09-10 | Regeneron Pharmaceuticals, Inc. | $22,108 | Research payment | Cash or cash equivalent | TCR SEQUENCING AND TRANSCRIPTIONAL PROFILING IN HLA B27 ASSOCIATED DISEASE | 2021 | |
| 2021-09-09 | DJO, LLC | $18,714 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-09-09 | Stryker Corporation | $500 | Research payment | Cash or cash equivalent | TRITANIUM Device, HIPS | MAVRIC MAGNETIC RESONANCE IMAGING USED TO STUDY DETAILED BONE APPOSITION AND FIXATION OF THE STRYKER TRIATHLON CEMENTLES | 2021 |
| 2021-09-09 | Alexion Pharmaceuticals, Inc. | $50 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravuli | 2021 | |
| 2021-09-08 | GE HEALTHCARE | $23,625 | Research payment | In-kind items and services | Development of Technology to Extend Scope of MRI in Orthopedic | 2021 | |
| 2021-09-03 | Regeneron Pharmaceuticals, Inc. | $27,778 | Research payment | Cash or cash equivalent | STUDY TO EVALUATE ARTHROPLASTY SPECIMENS IN THE PHASE 3 FASINUMAB PROGRAM FOR OSTEOARTHRITIS OF THE KNEE AND HIP | 2021 | |
| 2021-09-02 | Kadmon Corporation LLC | $40,214 | Research payment | Cash or cash equivalent | A Phase 2 Randomized Placebo controlled Double blind Open label Extension Multicenter Study to Evaluate the Efficacy and | 2021 | |
| 2021-09-02 | Stryker Corporation | $1,670 | Research payment | Cash or cash equivalent | RIO Device, ROBOTICS | SURVIVORSHIP AND OUTCOMES OF ROBOTIC ARM ASSISTED MEDIAL UKA | 2021 |
| 2021-09-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | $119 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Extension | 2021 |
| 2021-08-31 | UCB SA | $9,500 | Research payment | Cash or cash equivalent | Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis | 2021 | |
| 2021-08-31 | TREACE MEDICAL CONCEPTS, INC. | $4,966 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Lapiplasty System Device, Y | 2021 | |
| 2021-08-31 | UCB SA | $500 | Research payment | Cash or cash equivalent | Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis | 2021 | |
| 2021-08-30 | UCB SA | $40 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBL-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT | 2021 | |
| 2021-08-26 | Radius Health, Inc. | $90,113 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-08-26 | Novartis Pharmaceuticals Corporation | $4,350 | Research payment | Cash or cash equivalent | Biological | A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED MULTICENTER PHASE 2 DOSE RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF | 2021 |
| 2021-08-25 | Zimmer Biomet Holdings, Inc. | $13,325 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ROSA-Knee Device, Knees | 2021 | |
| 2021-08-25 | Zimmer Biomet Holdings, Inc. | $8,775 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ROSA-Knee Device, Knees | 2021 | |
| 2021-08-19 | Abbott Laboratories | $690 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-08-19 | UCB SA | $500 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF ROZANOLIXIZU | 2021 | |
| 2021-08-18 | Stryker Corporation | $3,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ACCOLADE Device, HIPS | 2021 | |
| 2021-08-18 | Stryker Corporation | $3,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | NA Device, ARTHROSCOPY | 2021 | |
| 2021-08-18 | Smith+Nephew, Inc. | $1,495 | Research payment | Cash or cash equivalent | JOURNEY II BCS Device, Recon Knees | A Retro-Prospective, Non-randomized, Consecutive Series, SIngle Cohort, Multicenter Adaptive Design Study to Evaluate th | 2021 |
| 2021-08-18 | Alexion Pharmaceuticals, Inc. | $135 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension | 2021 | |
| 2021-08-17 | Takeda Pharmaceuticals U.S.A., Inc. | $1,575 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2021 |
| 2021-08-17 | UCB SA | $1,180 | Research payment | Cash or cash equivalent | A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pre | 2021 | |
| 2021-08-17 | UCB SA | $50 | Research payment | Cash or cash equivalent | A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pre | 2021 | |
| 2021-08-16 | EXACTECH, INC. | $5,739 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VANTAGE Device, ORTHOPAEDIC | 2021 | |
| 2021-08-15 | Zimmer Biomet Holdings, Inc. | $7,500 | Grant | Cash or cash equivalent | Grants Device, General | 2021 | |
| 2021-08-15 | Zimmer Biomet Holdings, Inc. | $6,436 | Grant | Cash or cash equivalent | Grants Device, General | 2021 | |
| 2021-08-15 | Zimmer Biomet Holdings, Inc. | $5,461 | Grant | Cash or cash equivalent | Grants Device, General | 2021 | |
| 2021-08-15 | Zimmer Biomet Holdings, Inc. | $5,144 | Grant | Cash or cash equivalent | Grants Device, General | 2021 | |
| 2021-08-15 | Zimmer Biomet Holdings, Inc. | $4,734 | Grant | Cash or cash equivalent | Grants Device, General | 2021 | |
| 2021-08-15 | Zimmer Biomet Holdings, Inc. | $4,387 | Grant | Cash or cash equivalent | Grants Device, General | 2021 | |
| 2021-08-15 | Zimmer Biomet Holdings, Inc. | $3,949 | Grant | Cash or cash equivalent | Grants Device, General | 2021 | |
| 2021-08-15 | Medical Device Business Services, Inc. | $1,408 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-08-15 | Medical Device Business Services, Inc. | $791 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-08-15 | Medical Device Business Services, Inc. | $730 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-08-15 | Medical Device Business Services, Inc. | $721 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-08-15 | Medical Device Business Services, Inc. | $697 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-08-15 | Zimmer Biomet Holdings, Inc. | $566 | Grant | Cash or cash equivalent | Grants Device, General | 2021 | |
| 2021-08-15 | Medical Device Business Services, Inc. | $529 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-08-15 | Medical Device Business Services, Inc. | $265 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-08-15 | KCI USA, Inc. | $209 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-08-15 | KCI USA, Inc. | $68 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-08-13 | Ortho Development Corporation | $788 | Royalty or License | Cash or cash equivalent | Pagoda Device, ORTHOPEDIC DEVICE | 2021 | |
| 2021-08-12 | Stryker Corporation | $582 | Research payment | Cash or cash equivalent | TRITANIUM Device, HIPS | TRIDENT II TRITANIUM OUTCOMES STUDY | 2021 |
| 2021-08-12 | Stryker Corporation | $528 | Research payment | Cash or cash equivalent | SECUR-FIT Device, HIPS | SECURFIT ADVANCED OUTCOMES STUDY | 2021 |
| 2021-08-12 | Stryker Corporation | $250 | Research payment | Cash or cash equivalent | RESTORATION Device, HIPS | RESTORATION; ANATOMIC DUAL MOBILITY (ADM) X3; ACETABULAR SYSTEM STUDY WITH LONG TERM DATA COLLECTION FOR THE ACCOLADE; I | 2021 |
| 2021-08-11 | Alexion Pharmaceuticals, Inc. | $1,978 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension | 2021 | |
| 2021-08-09 | DePuy Synthes Products, Inc. | $10,712 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | RECLAIM Device, Ortho-Hip | 2021 | |
| 2021-08-09 | DePuy Synthes Products, Inc. | $10,712 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | RECLAIM Device, Ortho-Hip | 2021 |
The latest 200 records of 447.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In New York, NY, county Kings County, NY, state New York; placed by its city name.
| Measure | Place (city or town) New York, NY | County Kings County, NY | State New York |
|---|---|---|---|
| Population B01003 | 8,483,844 | 2,631,580 | 19,852,366 |
| Population, 2020 census P1 | 8,804,190 | 2,736,074 | 20,201,249 |
| Median age B01002 | 38.2 | 36.5 | 39.8 |
| Under 18 B01001 | 20.2% | 22.2% | 20.5% |
| 65 and over B01001 | 16.6% | 15.5% | 17.9% |
| Households B11001 | 3,334,088 | 1,009,927 | 7,722,646 |
| Foreign born B05002 | 36.6% | 35.3% | 22.8% |
| Median household income B19013 | $80,483 | $80,263 | $85,974 |
| Median family income B19113 | $91,707 | $88,947 | $106,873 |
| Per capita income B19301 | $51,844 | $47,575 | $50,712 |
| Poverty rate B17001 | 17.9% | 19.1% | 14.0% |
| Unemployment rate B23025 | 8.0% | 7.9% | 6.4% |
| Civilian labor force B23025 | 4,392,297 | 1,353,361 | 10,171,766 |
| Mean commute (minutes) B08013 | 40.3 | 41.7 | 32.6 |
| Bachelor's degree or higher B15003 | 41.6% | 42.1% | 40.2% |
| Housing units B25001 | 3,678,486 | 1,100,772 | 8,585,241 |
| Owner-occupied B25003 | 32.8% | 29.5% | 54.3% |
| Renters B25003 | 67.2% | 70.5% | 45.7% |
| Median home value B25077 | $777,600 | $905,000 | $423,800 |
| Median gross rent B25064 | $1,821 | $1,833 | $1,621 |
| White, not Hispanic B03002 | 31.0% | 36.1% | 52.8% |
| Black B03002 | 20.4% | 26.6% | 13.4% |
| Hispanic or Latino B03002 | 28.5% | 19.0% | 19.8% |
| Asian B03002 | 14.6% | 12.1% | 9.0% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in New York, NY.
Comments